SOM Biotech is a biopharmaceutical company focused on the accelerated discovery and development of therapies for orphan indications through a proprietary artificial intelligence-based drug discovery technology and developing strategic partnerships with major research centers and pharmaceutical companies.
SOM AI PRO Technology is a proprietary AI-based validated drug discovery technology of SOM Biotech. After defining drug candidates through the technology, we successfully finished the Clinical Phase 2a of two drugs with very positive results. This will contribute to treating two relevant neurodegenerative diseases more effectively, meeting high safety and tolerance standards.
One of our programs, for TTR Amyloidosis, after obtaining positive phase 2a results was out-licensed to NY based company. We have 3 programs in the preclinical stage, and 20 more programs in the early-stage pipeline, all obtained through the technology.
We aim at developing value-creating collaborations with strategic partners, to leverage on the large intrinsic potential of SOMAI-PRO to discover new treatments to tackle some of the most acute diseases to accelerate the drug discovery process.
Follow us on:
https://twitter.com/SOMBIOTECH
For collaborations:
zimina@sombiotech.com
SOM AI PRO Technology is a proprietary AI-based validated drug discovery technology of SOM Biotech. After defining drug candidates through the technology, we successfully finished the Clinical Phase 2a of two drugs with very positive results. This will contribute to treating two relevant neurodegenerative diseases more effectively, meeting high safety and tolerance standards.
One of our programs, for TTR Amyloidosis, after obtaining positive phase 2a results was out-licensed to NY based company. We have 3 programs in the preclinical stage, and 20 more programs in the early-stage pipeline, all obtained through the technology.
We aim at developing value-creating collaborations with strategic partners, to leverage on the large intrinsic potential of SOMAI-PRO to discover new treatments to tackle some of the most acute diseases to accelerate the drug discovery process.
Follow us on:
https://twitter.com/SOMBIOTECH
For collaborations:
zimina@sombiotech.com
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Health Tec... | hthvc.com |
Mentions in press and media 6
| Date | Title | Description |
| 08.03.2019 | Daily funding roundup - March 8th, 2019 | Bid Ops raised $1.75M; Jargon raised $1.8M; DesireList raised $3M; Osano raised $3M Bid Ops: Bid Ops accelerates business partnerships between leading buyers and top suppliers. Bid Ops has raised $1.75 million in seed funding co-led by Illu... |
| 08.03.2019 | SOM Biotech cierra una ronda de financiación de €7 millones liderada por una sociedad inversora, acuden varios socios actuales | 08/03/2019 Nota de prensa SOM BIOTECH CIERRA UNA RONDA DE €7 MILLONES LIDERADA POR UNA SOCIEDAD INVERSORA, ACUDEN VARIOS SOCIOS ACTUALES. La biofarmacéutica SOM Biotech –con sede en el Parc Científic de Barcelona (PCB) y especializada en... |
| 08.03.2019 | Term Sheet — Friday, March 8 | MEET THE DEALMAKERS We all know the stats. Only 2% of venture funding went to female founders, and just 8% of partners at the top venture capital firms are women. But in honor of International Women’s Day, I decided to highlight something e... |
| 23.01.2017 | SOM Biotech cierra una ronda de €2 millones, acuden 18 business angels | 23/01/2017 SOM BIOTECH CIERRA UNA RONDA DE €2 MILLONES, ACUDEN 18 BUSINESS ANGELS. La compañía biofarmacéutica SOM Biotech, especializada en el reposicionamento de fármacos para tratar enfermedades minoritarias del sistema nervioso y con ... |
| 20.01.2015 | Innova31 vende el 12% de Som Innovation a sus socios fundadores | 20/01/2015 INNOVA31 VENDE EL 12% DE SOM INNOVATION A SUS SOCIOS FUNDADORES. La entidad de capital riesgo (private equity) Innova31, ha vendido el 12% que mantenía en Som Innovation Biotech al vehículo inversor de los antiguos propietarios... |
| 21.03.2011 | Innova 31, 6 business angels y fondos públicos entran en Som Biotech | 21/03/2011 Nota de Prensa INNOVA 31, 6 BUSINESS ANGELS Y FONDOS PÚBLICOS ENTRAN EN SOM BIOTECH. La entidad de capital riesgo (venture capital) Innova31 ha tomado el 19% de Som Biotech en el marco de la primera ronda de financiación con c... |